Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 15/20 | 0.66 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25543874 | 0.87 | ALDH1A1 (0.53) | HCAR3HCAR2ALDH1A1LMNACYP2C19 | |
| SCHEMBL3466195 | 0.85 | NNMT (0.63) | HCAR3ALDH1A1LMNACYP2C19HDAC1 | |
| SCHEMBL19728674 | 0.84 | ALDH1A1 (0.56) | HCAR3ALDH1A1LMNACYP2C19HDAC1 | |
| SCHEMBL10932724 | 0.83 | HCAR3 (0.57) | HCAR3HCAR2HDAC1 | |
| SCHEMBL9772954 | 0.81 | ALDH1A1 (0.51) | HCAR3HCAR2ALDH1A1LMNACYP2C19 | |
| SCHEMBL4896861 | 0.81 | ALDH1A1 (0.51) | HCAR3HCAR2ALDH1A1LMNACYP2C19 | |
| SCHEMBL82675 | 0.81 | HCAR3 (0.68) | HCAR3HCAR2 | |
| SCHEMBL1586330 | 0.81 | HCAR3 (0.67) | HCAR3HCAR2 | |
| SCHEMBL9891790 | 0.79 | RAB9A (0.68) | ALDH1A1LMNACYP2C19RAB9ANPC1 | |
| SCHEMBL10935004 | 0.79 | MME (0.56) | HCAR3HCAR2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| EP-3724197-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019116256-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-20 | — | — | WO | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HCAR3 2703/4885HCAR2 1991/4885ALDH1A1 1067/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | HCAR3 2177/4885HCAR2 1639/4885ALDH1A1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.